Application of combination of astragalus polysaccharide and CAR-T in treatment of hepatocellular carcinoma

Through the combined treatment of astragalus polysaccharide and CAR-T cells, memory CAR-T cells are induced, which solves the problem of rapid depletion of CAR-T cells, significantly improves the therapeutic effect on hepatocellular carcinoma, and provides a safe and economical Integrated Western medicine plan.

CN119040270APending Publication Date: 2024-11-29GUANGDONG HOSPITAL OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411053739.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing CAR-T cells have poor effect on the treatment of hepatocellular carcinoma (HCC), mainly due to the rapid depletion of CAR-T cells and the lack of effective treatment plans for combining traditional Chinese and Western medicine.

Method used

Using a combination of Astragalus polysaccharide and CAR-T cells, memory CAR-T cells, especially CD122+CXCR3+ memory CD8+CAR-T cells were induced in vitro environment through Astragalus polysaccharide aqueous solution. Proliferation and differentiation, reduce the level of PD-1+ regulatory T cells, and improve the proliferation and chemotaxis/migration ability of CAR-T cells.

Benefits of technology

It significantly improves the therapeutic effect of CAR-T cells on HCC, extends the survival time of CAR-T cells, enhances the ability to inhibit tumors, and reduces side effects, providing a low-cost and safe treatment plan for integrated traditional Chinese and Western medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119040270A_ABST
    Figure CN119040270A_ABST
Patent Text Reader

Abstract

The invention discloses application of combination of astragalus polysaccharide and CAR-T in treatment of hepatocellular carcinoma. It is found for the first time that low-dose astragalus polysaccharide combined with CAR-T cells can significantly improve the HCC treatment effect of CAR-T. An established NOD / SCID mouse tumor model finds that treatment by combining astragalus polysaccharide with CAR-T can promote inhibition of CAR-T on HCC tumors, improve the level of CD122 + CXCR < 3 + > memory CD8 + CAR-T cells in tumor-bearing mice and reduce the level of PD-1 + regulatory T cells, so that the CAR-T cells have higher multiplication capacity, lower exhaustion degree and higher chemotactic / migration capacity, and the CAR-T cells can be used for treating HCC tumors. Therefore, the treatment effect of CAR-T on HCC is greatly improved. Moreover, the astragalus polysaccharide has the characteristics of wide source, low price, small side effect and good safety, and can be used for preparing the medicine for treating the hepatocellular carcinoma in combination with CAR-T.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and specifically relates to the application of astragalus polysaccharide combined with CAR-T in the treatment of hepatocellular carcinoma. Background Art

[0002] Hepatocellular carcinoma (HCC) is one of the most common types of liver cancer in the world and one of the most deadly cancers, accounting for 90% of primary liver cancers. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are major risk factors for HCC. In addition, alcoholic liver disease, autoimmune liver disease and metabolic disorders are increasing and becoming major factors in the growth of HCC.

[0003] Like most cancers, the development of HCC is a multi-step process, and the interaction between tumor cells and the microenvironment fundamentally affects the development of cancer. Persistent active hepatitis and liver fibrosis lead to a high recurrence rate of liver cancer, and the effects of liver resection and radiofrequency ablation as radical treatments for liver cancer are often unsatisfactory. Liver transplantation is the most radical method for treating liver cancer and underlying diseases including chronic hepatitis B, but there is a serious shortage of donors. Due to the limitations of various current treatment methods, the 5-year overall survival rate of HCC patients is very low, only 5% to 15%. Therefore, there is an urgent need to develop new methods to treat HCC.

[0004] Chimeric antigen receptor (CAR) is a fusion molecule that combines the recognition function of antibodies with the activation of T cells. CAR-modified T cells (CAR-T) are activated by recognizing antigens on the surface of target cells and initiate toxic killing of target cells. In recent years, CAR-T therapy has developed rapidly in the field of tumor treatment, especially in the treatment of hematological tumors. Scientists are currently working to apply this technology to the treatment of solid tumors including HCC. However, in most cases, due to factors such as the rapid exhaustion of CAR-T cells in the body, single CAR-T therapy cannot control tumors well. Because the rapid exhaustion of CAR-T cells is closely related to the high degree of differentiation of T cells, researchers have begun to try to intervene at the level of T cell differentiation to improve the problem of poor effect of CAR-T in the treatment of cancer due to rapid exhaustion. Memory T cells are believed to have stronger anti-tumor effects because they have better proliferation and differentiation capabilities and the ability to respond to repeated antigens.

[0005] In recent years, Chinese herbal medicine ingredients have shown significant advantages in tumor treatment, which can significantly improve and control clinical symptoms, improve the efficacy of anticancer drugs, reduce the toxicity of radiotherapy and chemotherapy, improve patients' immunity and quality of life, and effectively prolong survival time. Astragalus, a traditional Chinese medicine, is the dried rhizome of the leguminous plant Astragalus mongolicus or Astragalus membranaceus. It is one of the most traditional Chinese medicinal materials in my country. Its active ingredients mainly include polysaccharides, flavonoids, saponins and alkaloids. Among them, Astragalus polysaccharides (APS) are the most abundant natural active ingredients in Astragalus. It is composed of 9 monosaccharides such as glucan, galactose, arabinose, rhamnose, mannose, xylose, trehalose, fructose and ribose in different proportions. It has great potential in improving and treating a variety of diseases, and has also been reported to inhibit the growth of some types of tumors. However, there are no reports on the combination of Astragalus polysaccharides and CAR-T. The effect of Astragalus polysaccharides on the effect of CAR-T treatment of HCC is not known, and the effect of Astragalus polysaccharides on the differentiation of memory T cells is also unclear. Summary of the invention

[0006] The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art and provide an application of astragalus polysaccharide combined with CAR-T cells in the preparation of a drug for treating hepatocellular carcinoma. The combined treatment scheme of astragalus polysaccharide combined with CAR-T for the treatment of HCC overcomes the rapid exhaustion of CAR-T cells and improves the effect of treating HCC, provides data support for the combination of Chinese and Western medicine for the anti-tumor treatment of astragalus polysaccharide and CAR-T for the treatment of solid tumors, and has clinical application value.

[0007] The purpose of the present invention is achieved through the following technical solutions:

[0008] The application of Astragalus polysaccharide is any one or more of the following applications:

[0009] (1) Application of inducing memory CAR-T cells in vitro;

[0010] (2) Application in the preparation of memory CAR-T cell inducers.

[0011] Furthermore, the memory CAR-T cells include memory CD8 + CAR-T cells.

[0012] Furthermore, the memory CD8 + CAR-T cells include CD122 + CXCR3 + Memory CD8 + CAR-T cells, CD45RA + CCR7 + Memory CD8 + CAR-T cells and CD45RA- CCR7 + Memory CD8 + Any one or more of CAR-T cells.

[0013] Furthermore, the CAR-T cells are T cells modified with a chimeric antigen receptor targeting phosphatidylinositol proteoglycan-3 (GPC3).

[0014] Furthermore, the application (1) comprises:

[0015] Step 1): Obtaining initial CAR-T cells;

[0016] Step 2): Induce memory CAR-T cells in vitro.

[0017] Furthermore, the specific operation of step 1) is to separate CD3 + T cells are added to a well plate pre-coated with anti-human CD3 and CD28 antibodies, and stimulated and cultured in the presence of recombinant human interleukin 2 (IL-2) to obtain activated T cells; in the presence of protamine sulfate, the activated T cells are infected with a lentivirus containing the anti-GPC3 chimeric antigen receptor (GPC3-CAR) gene to obtain initial CAR-T cells.

[0018] Furthermore, the specific operation of step 2) is: the culture dish is pre-coated with antigen protein, then the initial CAR-T cells are inoculated, and an astragalus polysaccharide aqueous solution prepared with culture medium is added to induce memory CAR-T cells in an in vitro environment.

[0019] Furthermore, the effective concentration of astragalus polysaccharide in vitro is 400-800 μg / mL. This concentration can increase CD122 + CXCR3 + Memory CD8 + CAR-T cells reduce PD-1 + Levels of regulatory T cells.

[0020] The application of astragalus polysaccharide combined with CAR-T cells in the preparation of anti-tumor drugs, wherein the tumor includes any one or more tumors that specifically express phosphatidylinositol proteoglycan-3 (GPC3).

[0021] Furthermore, the tumor includes any one or more of hepatocellular carcinoma, non-small cell lung cancer, ovarian clear cell carcinoma, melanoma, lung squamous cell carcinoma, hepatoblastoma and Wilms' tumor.

[0022] Furthermore, the tumor is hepatocellular carcinoma.

[0023] Furthermore, the chimeric antigen receptor of the CAR-T cell is a chimeric antigen receptor targeting phosphatidylinositol proteoglycan-3 (GPC3).

[0024] Furthermore, the astragalus polysaccharide includes astragalus polysaccharide and pharmaceutically acceptable salts thereof.

[0025] Furthermore, the astragalus polysaccharide includes a plant extract with astragalus polysaccharide as a main active ingredient.

[0026] Furthermore, the astragalus polysaccharide is in an oral dosage form or an injection form.

[0027] Furthermore, the oral dosage forms include but are not limited to solutions, granules, tablets, capsules and all other dosage forms that can be achieved by technology, as well as all dosage forms that can be prepared with pharmaceutical excipients.

[0028] Furthermore, the injection dosage forms include but are not limited to solutions, granules, tablets, capsules and all other dosage forms that can be achieved by technology, as well as all dosage forms that can be prepared with pharmaceutical excipients.

[0029] Furthermore, the dosage of astragalus polysaccharide is 50-200 mg / kg of mouse body weight / day, preferably 50-100 mg / kg of mouse body weight / day. The above dosage can achieve a good effect of promoting CAR-T cell treatment of HCC.

[0030] The CAR-T cells are CAR-T cells targeting the GPC3 molecules on the surface of hepatocellular carcinoma.

[0031] The CAR-T cell targeting antigens for combined treatment with astragalus polysaccharide include but are not limited to GPC3.

[0032] The present invention found that the combined use of astragalus polysaccharide and CAR-T has a significant therapeutic effect on subcutaneous tumors in mice established by human Huh7 and HepG2 liver cancer cells: compared with CAR-T treatment alone, astragalus polysaccharide promoted the inhibition of HCC tumors by CAR-T and increased the expression of CD122 in tumor-bearing mice. + CXCR3 + Memory CD8 + The level of CAR-T cells decreased PD-1 + The level of regulatory T cells makes CAR-T cells have stronger proliferation ability, lower exhaustion degree and stronger chemotaxis / migration ability, thus greatly improving the therapeutic effect of CAR-T on HCC. At the in vitro cell level, it is also confirmed that Astragalus polysaccharides increase CD8 + The expression levels of CD122 and CXCR3 in CAR-T cells were increased, and the expression of PD-1 was reduced.

[0033] According to the above results, plant extracts containing astragalus polysaccharide components also have the effect of promoting CAR-T treatment of HCC. Therefore, the present invention claims to protect the use of all plant extracts containing astragalus polysaccharide combined with CAR-T in the treatment of hepatocellular carcinoma.

[0034] Compared with the prior art, the present invention has the following advantages and effects:

[0035] This paper first discovered that low-dose astragalus polysaccharide combined with CAR-T cells can significantly improve the effect of CAR-T in treating HCC. Through the established NOD / SCID mouse tumor model, it was found that astragalus polysaccharide combined with CAR-T treatment can promote CAR-T's inhibition of HCC tumors and increase the expression of CD122 in tumor-bearing mice. + CXCR3 + Memory CD8 + CAR-T cells reduce PD-1 + The level of regulatory T cells makes CAR-T cells have stronger proliferation ability, lower exhaustion degree and stronger chemotaxis / migration ability, thus greatly improving the therapeutic effect of CAR-T on HCC. In addition, astragalus polysaccharide has the characteristics of wide source, low price, few side effects and good safety, and can be used to prepare drugs for combined CAR-T treatment of hepatocellular carcinoma. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 Figure 2 is the tumor growth during treatment and the Huh7 subcutaneous tumor status after treatment, as well as the presence of CAR-T cells in vivo and the tumor infiltration status; *p<0.05, **p<0.01.

[0037] Figure 2 CD8 in Huh7 subcutaneous tumor-bearing mice after treatment + Expression levels of CD122, CXCR3 and PD-1 in CAR-T cells; *p<0.05, **p<0.01.

[0038] Figure 3 Figure 2 is a graph showing tumor growth during treatment and HepG2 subcutaneous tumor status after treatment; *p<0.05, **p<0.01.

[0039] Figure 4 Flow cytometry was used to detect CD8 + Expression of CD122, CXCR3 and PD-1 in CAR-T cells; *p<0.05, **p<0.01. DETAILED DESCRIPTION

[0040] The present invention is further described in detail below in conjunction with the embodiments and drawings, but the embodiments of the present invention are not limited thereto. In order to facilitate the public to better understand the present invention, the beneficial effects of the present invention are further described below in conjunction with the drawings and specific embodiments of the specification, but it should be noted that the embodiments of the present invention do not limit the present invention in any form.

[0041] The CAR-T cells used in the following examples were prepared by the following method:

[0042] HEK293T cells were co-transfected with psPAX2 and pMD2 to produce recombinant lentiviral particles containing a chimeric antigen receptor targeting GPC3 (GPC3-CAR) gene. The supernatant was then filtered and concentrated 30 times by ultracentrifugation. Human peripheral blood mononuclear cells (PBMCs) were isolated from the peripheral blood of healthy volunteers using a lymphocyte isolation kit, and CD3 T cells were isolated from PBMCs using the EasySep Human T Cell Isolation Kit. + T cells. CD3 + T cells were added to 24-well plates pre-coated with anti-human CD3 and CD28 antibodies and cultured for 3 days with 100 U / mL recombinant human interleukin 2 (IL-2). After 48 hours of T cell activation, 5×10 cells were infected with 500 μL of lentivirus carrying GPC3-CAR in the presence of 10 mg / mL protamine sulfate (110123, Sigma-Aldrich). 5 T cells were centrifuged at 1000 rpm and 30 degrees Celsius for 1 hour. After centrifugation, T cells were incubated overnight in a 37°C, 5% CO2 incubator in the presence of complete RPMI-1640 medium and 100U / mL IL-2. The next day, fresh RPMI1640 medium containing 100U / mL IL-2 was replaced and transferred to a new culture dish to obtain the CAR-T cells. The single chainantibody fragment (scFV) gene sequence of the antigen recognition region contained in GPC3-CAR:

[0043] The heavy chain sequence is: CAGGTTCAACTGCAGCAGTCTGGGGCTGAGCTGGTGAGGCCTGGGGC TTCAGTGAAGCTGTCCTGCAAGGCTTCGGGCTACACATTTACTGACTATGAAATGCACTGGGTGAAGCAGACACCTGTGCATGGCCTAAAATGGATTGGAGCTCTTGATCCTAAAACTGGTGATACTGCCTACAGTCAGAAGTTCAAGG GCAAGGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGGAGCTCCGCAGCCTGACATCTGAGGACTCTGCCGTCTATTACTGTACAAGATTCTACTCCTATACTTACTGGGGCCAAGGGACTCTGGTCACTGTCTCTGCA;

[0044] The light chain sequence is: GATGTTGTGATGACCCAAACTCCACTCTCCCTGCCTGTCAGTCTTGGA GATCAAGCCTCCATCTCTTGCAGATCTAGTCAGAGCCTTGTACACAGTAATGGAAACACCTATTTACATTGGTACCTGCAGAAGCCAGGCCAGTCTCCAAAGCTCCTGATCTACAAAGTTTCCAACCGATTTTCTGGGGTCCCA GACAGGTTCAGTGGCAGTGGATCAGGGACAGATTTCACACTCAAGATCAGCAGAGTGGAGGCTGAGGATCTGGGAGTTTATTTCTGCTCTCAAAATACACATGTTCCTCCTACGTTCGGATCGGGGACCAAGCTGGAAATAAAA.

[0045] Example 1

[0046] In order to explore the effect of astragalus polysaccharide (APS) on CAR-T treatment of hepatocellular carcinoma (HCC), the present invention used human Huh7 and HepG2 liver cancer cell lines to construct a subcutaneous tumor model, and took the astragalus polysaccharide aqueous solution as an example to design the following animal experiments:

[0047] Adding astragalus polysaccharide into physiological saline to prepare an astragalus polysaccharide aqueous solution with a concentration of 10 mg / mL;

[0048] Twenty NOD / SCID mice were subcutaneously inoculated in the right axilla of each mouse with 100 μL of tumor cells (5×106 Huh7 cells or 2×10 6 HepG2 cells) in PBS. Five days after tumor cell inoculation, the tumor-bearing mice were randomly divided into four groups, namely, solvent control group (vehicle), astragalus polysaccharide treatment group (APS), CAR-T treatment group (CAR-T), and astragalus polysaccharide combined with CAR-T treatment group (APS+CAR-T). Starting from the day of grouping, except for the vehicle group which was given oral 0.9% normal saline, the APS group and APS+CAR-T group took astragalus polysaccharide (50 mg / kg) orally every day until the end of the experiment. Two days before the injection of CAR-T cells, all mice received a single intraperitoneal injection of cyclophosphamide (200 mg / kg). Ten days after tumor cell inoculation, mice in the CAR-T group and APS+CAR-T group were injected with 5×10 6 CAR-T cells were added. The weight of mice was measured every 3 days, and the size of tumors was measured with a vernier caliper. When the diameter of tumors in some mice reached about 1.5 cm, the mice were killed, and blood, spleen and tumors were collected for experimental analysis.

[0049] In order to intuitively confirm the effect of astragalus polysaccharide (APS) on CAR-T cells at the cellular level, salvia miltiorrhiza polysaccharide was used as a control and the following cell experiments were designed:

[0050] Astragalus polysaccharide and Salvia miltiorrhiza polysaccharide were prepared into 10 mg / mL aqueous solution using 1640 complete medium. 96-well plates were pre-coated with 5 μg / mL GPC3 protein at 4°C overnight, and CAR-T cells were plated at 1×10 5 Each well was inoculated in a 96-well plate and cultured with different concentrations (0 / 200 / 400 / 800 μg / mL) of astragalus polysaccharide or salvia polysaccharide. After 96 hours, CAR-T cells were stained and analyzed by flow cytometry.

[0051] result:

[0052] (1) Effect of Astragalus polysaccharide on CAR-T therapy for HCC (Huh7 cells) subcutaneous tumors

[0053] Figure 1 A in the figure shows the experimental implementation scheme. Figure 1 B in the figure shows the growth curves of the tumors in each group during the treatment process. Figure 1 C in the figure shows the weight of tumors in each group after treatment. Figure 1 D in the figure shows the images of the tumors in each group after treatment. Figure 1 EG in the figure shows the number of T cells in the blood, spleen and tumor of mice in the CAR-T group and APS+CAR-T group after treatment. Figure 1 HI in tumors showed CD8 +Infiltration of T cells, Figure 1 J in the figure shows the levels of IFN-γ, TNF-α, TGF-β, and IL-10 in tumors. Figure 1 The K in the figure shows the levels of CXCL9 and CXCL10 in the tumor. The results showed that compared with the control group, this dose of astragalus polysaccharide could not significantly inhibit Huh7 tumor growth, and CAR-T treatment significantly inhibited tumor growth. Compared with the CAR-T treatment group, astragalus polysaccharide combined with CAR-T treatment more significantly inhibited tumor growth. Compared with the CAR-T group, the total T cells and CD8 + Compared with the CAR-T group, the number of CD8 + There were more T cells, increased anti-tumor factors IFN-γ, TNF-α and chemokines CXCL9 / CXCL10, and decreased immunosuppressive factors TGF-β and IL-10. The results showed that the combination of astragalus polysaccharide and CAR-T cells had a better therapeutic effect on Huh7 tumor mice, which was probably achieved by astragalus polysaccharide promoting the proliferation / survival and chemotaxis / migration ability of CAR-T.

[0054] (2) Effect of Astragalus polysaccharide on CD8 + Effect of CAR-T cell CD122, CXCR3 and PD-1 expression levels

[0055] Figure 2 After treatment, the CD8 + CAR-T cell CD122, CXCR3 ( Figure 2 AB in) and PD-1( Figure 2 The results showed that astragalus polysaccharide increased the expression of CD8 + The percentage of CD122 and CXCR3 positive cells in CAR-T cells was increased, and the percentage of PD-1 positive cells was reduced. The results showed that astragalus polysaccharide may be through increasing CD8 + CD122 in CAR-T cells + CXCR3 + PD-1 - Levels of memory T cells, which reduce PD-1 + The level of regulatory T cells can be used to promote the effect of CAR-T in treating HCC.

[0056] (3) Effect of Astragalus polysaccharide on CAR-T therapy for HCC (HepG2 cells) subcutaneous tumors

[0057] Figure 3A in the figure shows the growth curve of tumors in each group during treatment. Figure 3 B in the figure shows the weight of tumors in each group after treatment. Figure 3 C in the figure shows the images of the tumors in each group after the treatment. The results showed that compared with the control group, APS or CAR-T alone significantly inhibited the growth of HepG2 tumors. Compared with CAR-T alone, APS+CAR-T combined treatment further inhibited tumor growth. The results showed that APS can also enhance the anti-tumor effect of CAR-T in the HCC model constructed by HepG2 cells.

[0058] (4) Effect of Astragalus polysaccharide on CD8 + Effect of CAR-T cell CD122, CXCR3 and PD-1 expression levels

[0059] Figure 4 It shows that CD8 + CD122 and CXCR3 ( Figure 4 A) and PD-1( Figure 4 The results showed that 400 μg / mL and 800 μg / mL of Astragalus polysaccharide significantly increased the expression of CD8 + The mean fluorescence intensity (MFI) of CD122 and CXCR3 expression in CAR-T cells was increased, and the expression level (MFI) of PD-1 was reduced. As a control, 400 μg / mL and 800 μg / mL of Danshen polysaccharide had no significant effect on CD8 + There was almost no effect on the expression of CD122, CXCR3 and PD-1 in CAR-T cells.

[0060] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. The application of astragalus polysaccharide is characterized by: Any one or more of the following applications: (1) Application of inducing memory CAR-T cells in vitro; (2) Application in the preparation of memory CAR-T cell inducers.

2. The use of astragalus polysaccharide according to claim 1, characterized in that: The memory CAR-T cells include memory CD8 + CAR-T cells; The memory CD8 + CAR-T cells include CD122 + CXCR3 + Memory CD8 + CAR-T cells, CD45RA + CCR7 + Memory CD8 + CAR-T cells and CD45RA - CCR7 + Memory CD8 + Any one or more of CAR-T cells.

3. The use of astragalus polysaccharide according to claim 1, characterized in that: The CAR-T cells are T cells modified with a chimeric antigen receptor targeting glycan-3.

4. The use of astragalus polysaccharide according to any one of claims 1 to 3, characterized in that: The application (1) comprises: Step 1): Obtaining initial CAR-T cells; Step 2): Induce memory CAR-T cells in vitro.

5. The use of astragalus polysaccharide according to claim 4, characterized in that: The specific operation of step 1) is to separate CD3 + T cells are added to a well plate pre-coated with anti-human CD3 and CD28 antibodies, and stimulated and cultured in the presence of recombinant human interleukin 2 to obtain activated T cells; in the presence of protamine sulfate, the activated T cells are infected with a lentivirus containing an anti-GPC3 chimeric antigen receptor gene to obtain initial CAR-T cells; The specific operation of step 2) is as follows: the culture dish is pre-coated with antigen protein, then the initial CAR-T cells are inoculated, and the prepared astragalus polysaccharide aqueous solution is added to induce memory CAR-T cells in an in vitro environment; The effective concentration of the astragalus polysaccharide in vitro is 400-800 μg / mL.

6. Application of astragalus polysaccharide combined with CAR-T cells in the preparation of anti-tumor drugs, characterized in that: The tumor includes any one or more of the tumors that specifically express phosphatidylinositol proteoglycan-3.

7. The use of astragalus polysaccharide combined with CAR-T cells in the preparation of anti-tumor drugs according to claim 6, characterized in that: The tumor includes any one or more of hepatocellular carcinoma, non-small cell lung cancer, ovarian clear cell carcinoma, melanoma, lung squamous cell carcinoma, hepatoblastoma and Wilms' tumor.

8. The use of astragalus polysaccharide combined with CAR-T cells in the preparation of anti-tumor drugs according to claim 6, characterized in that: The tumor is hepatocellular carcinoma; The chimeric antigen receptor of the CAR-T cell is a chimeric antigen receptor targeting phosphatidylinositol proteoglycan-3.

9. The use of astragalus polysaccharide combined with CAR-T cells in the preparation of anti-tumor drugs according to any one of claims 6 to 8, characterized in that: The astragalus polysaccharide includes astragalus polysaccharide and pharmaceutically acceptable salts thereof; The astragalus polysaccharide comprises a plant extract with astragalus polysaccharide as the main active ingredient; The astragalus polysaccharide is in oral dosage form or injection form; The oral dosage forms include solutions, granules, tablets and capsules; The injection dosage forms include solutions, granules, tablets and capsules.

10. The use of astragalus polysaccharide combined with CAR-T cells in the preparation of anti-tumor drugs according to any one of claims 6 to 8, characterized in that: The dosage of the astragalus polysaccharide is 50-200 mg / kg body weight of mouse / day.